What is the role of tadalafil for the treatment of pulmonary arterial hypertension (PAH)?

Updated: Apr 25, 2018
  • Author: Kristin E Schwab, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Tadalafil is a PDE5 inhibitor indicated for improving exercise capacity in patients with PAH. [63] It increases cGMP, the final mediator in the nitric oxide pathway. It is indicated as a single agent for improving exercise capacity in patients with PAH, as well as in combination with ambrisentan based on the AMBITION trial (per above). It is dosed as a once-daily medication and has a similar adverse effect profile as sildenafil.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!